Grifols SA GRFS

Latest FY: 2025 Healthcare Drug Manufacturers - General
Market Price $7.57
Market Cap $1.95B
P/E Ratio N/A
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑4.3% YoY
$7.52B
3-Yr CAGR: 7.2%
Net Income ↑75.4% YoY
$98.00M
Net Margin: 1.3%
Free Cash Flow ↓-1,186.0% YoY
-$430.00M
FCF Yield: -22.00%
EPS (Diluted)
N/A
Basic: N/A
Return on Equity Efficiency
1.8%
ROA: 0.5%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (GRFS)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Div / Sh Div Yield Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $4,049.8M $1,912.3M $-0.9M 0.00% $215.3M
FY 2017 $4,318.1M +6.6% $2,152.0M $-1.4M -51.8% 0.00% $147.0M $-104.5M
FY 2018 $4,486.7M +3.9% $2,049.6M $-2.2M -61.3% 0.00% $111.6M $-120.4M -15.2%
FY 2019 $5,098.7M +13.6% $2,341.2M $23.5M +1,150.9% 0.00% $107.8M $-202.6M -68.3%
FY 2020 $5,340.0M +4.7% $2,255.2M $90.4M +284.9% 0.00% $131.5M $-148.6M +26.6%
FY 2021 $4,965.7M -7.0% $1,962.6M $76.6M -15.3% 0.00% $30.6M $-216.8M -45.8%
FY 2022 $6,108.4M +23.0% $2,231.5M $62.9M -17.9% 0.00% $196.4M $-84.1M +61.2%
FY 2023 $6,592.0M +7.9% $2,494.6M $121.4M +93.0% 0.00% $158.9M $-42.1M +49.9%
FY 2024 $7,212.4M +9.4% $2,794.5M $55.9M -53.9% 0.00% $175.6M $-33.4M +20.7%
FY 2025 $7,524.0M +4.3% $2,859.0M $98.0M +75.4% 0.00% $-169.0M $-430.0M -1,186.0%
$

Valuation

Market Price $7.57
Market Cap $1.95B
Enterprise Value $1.13B
P/E Ratio N/A
P/B Ratio 0.36
FCF Yield -22.00%
Dividend Yield 0.00%
Shares Outstanding 258,223,442
%

Profitability & Margins

Gross Margin 38.00%
Operating Margin 16.52%
Net Margin 1.30%
Return on Equity (ROE) 1.82%
Return on Assets (ROA) 0.50%
Asset Turnover 0.38x
Revenue 3-Yr CAGR 7.19%
🛡️

Financial Health & Liquidity

Current Ratio 21.67
Cash Ratio 275.00
Debt / Equity 0.000
Debt / Assets 0.000
Cash & Equivalents $825.00M
Total Debt N/A
Book Value / Share $20.85
💧

Cash Flow Efficiency

Operating Cash Flow -$169.00M
Capital Expenditures (CapEx) $261.00M
Free Cash Flow -$430.00M
OCF / Revenue -2.25%
FCF / Revenue -5.72%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) N/A
EPS (Basic) N/A
Dividends / Share N/A
Book Value / Share $20.85
EPS YoY Growth N/A
🏛️

Balance Sheet (FY 2025)

Total Assets $19.71B
Total Liabilities $14.33B
Stockholders' Equity $5.38B
Current Assets $65.00M
Current Liabilities $3.00M